Cardica
This article was originally published in The Gray Sheet
Executive Summary
Results of a 100-patient trial of Cardica's C-Port distal anastomosis system for cardiac bypass are presented by Michael Mack, MD, Cardiothoracic Surgery Associates of North Texas at the European Association for Cardiothoracic Surgery/European Society of Thoracic Surgeons joint meeting in Leipzig, Germany Sept. 13. Patency of bypass vessels attached with C-Port was 96.9% after six months, compared to 84.9% in historical studies. Cardica, which is 20% owned by Guidant, will use the data to support a CE mark and 510(k) indication in the coming months, the firm says...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.